

 Formulary Hazardous Drug List
Group 1. Antineoplastic Drugs (12)

Including those with the manufacturer's safe-handling guidance (MSHG)

anastrozole	10:00		FDA Pregnancy Category X
bacillus calmette guerin	80:12	MSHG	BCG, although classified as a vaccine, is used in the treatment of certain cancers. BCG should be prepared with aseptic techniques. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A separate area for the preparation of BCG suspension is recommended. All equipment, supplies, and receptacles in contact with BCG should be handled and disposed of as biohazardous. If preparation cannot be performed in a containment device, then respiratory protection, gloves, and a gown should be worn to

			avoid inhalation or contact with BCG organisms. FDA Pregnancy Category C
bleomycin	10:00	MSHG	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category D
fluorouracil	10:00	MSHG	FDA Pregnancy Category D
gemcitabine	10:00	MSHG	FDA Pregnancy Category D
hydroxyurea	10:00	MSHG	Special warning on handling bottles and capsules; FDA Pregnancy Category D
letrozole	10:00		FDA Pregnancy Category X
leuprolide	10:00	MSHG	FDA Pregnancy Category X
megestrol	10:00		Nursing should be discontinued if megestrol is required; women at risk of pregnancy should avoid exposure; FDA Pregnancy Category X
mercaptopurine	10:00	MSHG	FDA Pregnancy Category D
methotrexate	10:00	MSHG	FDA Pregnancy Category X
mitomycin	10:00	MSHG	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category D

Group 2. Non-antineoplastic Drugs (20)

That meet one or more of the NIOSH criteria for a hazardous drug, including those with the manufacturer's safe-handling guidance (MSHG)

Northeastern Vermont Regional Hospital

azathioprine	92:44	MSHG	<p>IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
carbamazepine	28:12:92		<p>Black Box warning for aplastic anemia; congenital malformations in offspring of mothers who took drug; rapid transplacental passage; FDA Pregnancy Category D</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
cyclosporin	92:44		<p>IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category C</p>
divalproex	28:12:92		<p>Black Box warning for teratogenicity; FDA Pregnancy Category D; tumors seen in laboratory studies at doses below MRHD</p> <p>Meets one or more criteria for a</p>

		hazardous drug and also poses a potential reproductive hazard
estradiol	68:16:04	<p>Black Box warning for malignant neoplasms; increased risk of endometrial cancer, breast cancer, and ovarian cancer; in laboratory studies, increased frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver; present in breast milk; FDA Pregnancy Category X</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
estrogen-progestin combinations	68:12	<p>IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
estrogens, conjugated	68:16:04	<p>Black Box warning for endometrial cancer and cardiovascular risks; long-term use in women and laboratory studies increases frequency of several cancers; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X</p>

		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
estrogens, esterified	68:16:04	Black Box warning for endometrial cancer and cardiovascular risks; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X
		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
fosphenytoin	28:12.12	Metabolized to phenytoin; FDA Pregnancy Category D
		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
medroxyprogesterone acetate	68:32	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category X
		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
methimazole	68:36:08	Appears in human breast milk; FDA Pregnancy Category D
		Meets one or more criteria for a

mycophenolate mofetil	92:44	<p>hazardous drug and also poses a potential reproductive hazard</p> <p>Black Box warning for embryo fetal toxicity, malignancies, and serious infections; increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; FDA Pregnancy Category D; Special warning: Tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in capsules and oral suspension(before or after constitution). If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
oxcarbazepine	28:12:92	<p>Tumors observed in laboratory studies at 1/10 MRHD; FDA Pregnancy Category C</p>
phenytoin	28:12.12	<p>IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D</p>

		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
propylthiouracil	68:36:08	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
raloxifene	68:16:12	Abortion and developmental abnormalities seen at low doses in laboratory studies; evidence of tumors at low doses in laboratory studies; FDA Pregnancy Category X Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
risperidone	28:16:08:04	As of January 10, 2019 this drug is no longer considered a hazardous drug by NIOSH. 2016 text: Evidence of tumors at low doses in laboratory studies; may be prolactin-mediated; FDA Pregnancy Category C

spironolactone	24:32.20		FDA Pregnancy Category C; Black Box warning for tumorigenicity in laboratory studies
tacrolimus	92:44		Increased risk of lymphomas and other malignancies; reproductive effects seen in laboratory studies below the MRHD; excreted in breast milk; FDA Pregnancy Category C
valganciclovir	8:18:32	MSHG	FDA Pregnancy Category C

Group 3. Non-antineoplastic Drugs (22)

That primarily have adverse reproductive effects

clonazepam	28:12:08		Increased risk of congenital abnormalities when taken in first trimester; FDA Pregnancy Category D
colchicine	92:16		FDA Pregnancy Category C; published animal reproduction and development studies indicate it causes embryofetal toxicity, teratogenicity, and altered postnatal development at exposures within or above the clinical therapeutic range
dinoprostone	76:00		Hazardous only for women in late pregnancy; FDA Pregnancy Category C
dronedarone	24:04:04		Teratogenic in laboratory studies at ½ MRHD; FDA Pregnancy Category X

dutasteride	92:08	Women warned not to handle; FDA Pregnancy Category X Northeastern Vermont Regional Hospital
finasteride	92:08	Women should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant, due to potential risk to a male fetus; FDA Pregnancy Category X
fluconazole	8:14.08	FDA Pregnancy Category C; case reports describe congenital anomalies in infants exposed in utero to maternal fluconazole (400–800 mg/day) during most or all of the first trimester, similar to those seen in animal studies
methyltestosterone	68:08	FDA Pregnancy Category X
misoprostal	56:28.28	FDA Pregnancy Category X
oxytocin	76:00	Hazardous only for women in 3rd trimester; FDA Pregnancy Category C
pamidronate	92:24	Embryo-fetal toxicities at doses below the recommended human dose; FDA Pregnancy Category D
paroxetine	28:16:04:20	Increased risk of congenital abnormalities when taken in first trimester; complications in pregnancy when taken in third trimester; FDA Pregnancy Category D
temazepam	28:24:08	

Increased risk of congenital malformations associated with treatment during the first trimester of pregnancy; FDA Pregnancy Category X

testosterone	68:08	Children should avoid contact with unwashed or unclothed application sites on skin; FDA Pregnancy Category X
topiramate	28:12:92	FDA Pregnancy Category D
tretinoin	84:16	Black Box warning for severe birth defects; Special FDA distribution system; FDA Pregnancy Category X
valproate	28:12:92	Black Box warning for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species; FDA Pregnancy Category D
valproic acid	28:12:92	Black Box warning for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species; FDA Pregnancy Category D
warfarin	20:12.04.08	FDA Pregnancy Category D
ziprasidone	28:16:08:04	Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups

		born dead and a decrease in postnatal survival at less than MRHD; FDA Pregnancy Category C
zoledronic acid	92:24	Number of stillbirths increased and survival of neonates decreased in laboratory studies at low doses; FDA Pregnancy Category D
zonisamide	28:12:92	Teratogenic in multiple miscellaneous animal species; FDA Pregnancy Category D